Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

Alzheimer’s disease (AD) presents significant challenges in clinical practice due to its heterogeneous manifestation and variable progression rates. This work develops a comprehensive anatomical staging framework to predict progression from mild cognitive impairment (MCI) to AD. Using the ADNI database, the scalable Subtype and Stage Inference (s-SuStaIn) model was applied to 118 neuroanatomical features from cognitively normal (n = 504) and AD (n = 346) participants. The framework was validated on 808 MCI participants through associations with clinical progression, CSF and FDG-PET biomarkers, and neuropsychiatric measures, while adjusting for common confounders (age, gender, education, and APOE ε4 alleles). The framework demonstrated superior prognostic accuracy compared to traditional risk assessment (C-index = 0.73 vs. 0.62). Four distinct disease subtypes showed differential progression rates, biomarker profiles (FDG-PET and CSF Aβ42), and cognitive trajectories: Subtype 1, subcortical-first pattern; Subtype 2, executive–cortical pattern; Subtype 3, disconnection pattern; and Subtype 4, frontal–executive pattern. Stage-dependent changes revealed systematic deterioration across diverse cognitive domains, particularly in learning acquisition, visuospatial processing, and functional abilities. This data-driven approach captures clinically meaningful disease heterogeneity and improves prognostication in MCI, potentially enabling more personalized therapeutic strategies and clinical trial design.

Key findings

Why it matters

This study developed an anatomical staging framework using brain imaging data that predicted progression from MCI to Alzheimer's disease with better accuracy than traditional risk assessment, identifying four distinct disease subtypes with different progression rates. The work is about predicting progression and capturing disease heterogeneity, not about treating or curing the disease.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (International Journal of Molecular Sciences)
Journal's citation record 3 / 4 International Journal of Molecular Sciences: journal h-index 426 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 504 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Cassie S. Mitchell: h-index 23 (OpenAlex, whole career)
Institution's track record 2 / 3 New York University: institution h-index 1,612 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40564976)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Tandon, R., Mei, Y., Lah, J. J., & Mitchell, C. S. (2025). Comprehensive Anatomical Staging Predicts Clinical Progression in Mild Cognitive Impairment: A Data-Driven Approach. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125514

Vancouver

Tandon R, Mei Y, Lah JJ, Mitchell CS. Comprehensive Anatomical Staging Predicts Clinical Progression in Mild Cognitive Impairment: A Data-Driven Approach. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125514. PMID: 40564976.

BibTeX

@article{tandon2025-40564976,
  author  = {Tandon, Raghav and Mei, Yajun and Lah, James J. and Mitchell, Cassie S.},
  title   = {{Comprehensive Anatomical Staging Predicts Clinical Progression in Mild Cognitive Impairment: A Data-Driven Approach}},
  journal = {International Journal of Molecular Sciences},
  year    = {2025},
  doi     = {10.3390/ijms26125514},
  pmid    = {40564976},
  url     = {https://doi.org/10.3390/ijms26125514}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Mild cognitive impairment

Also tagged “assessment”

840 studies in the library carry the topic tag “assessment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →